Celgene Snags Cancer Treatment Co. Avila For $350M
The acquisition of Bedford, Mass.-based Avila and its AVL-292 treatment allows Celgene to further expand its research of novel therapies for hematology, oncology and autoimmune diseases, Celgene said. Depending on the development and regulatory approval of AVL-292, Celgene may pay up to $195 million in additional milestone payments under the deal, Celgene said.
Celgene viewed Avila’s approach...
To view the full article, register now.